Browsing Tag
argenx SE
3 posts
Why argenx is buying Forte Biosciences before FB102 enters its bigger proof stage
argenx agrees to buy Forte Biosciences for $2.2 billion. Read how FB102 could reduce Vyvgart concentration risk and reshape ARGX’s autoimmune strategy.
Could FcRn blockers become the next biologics blockbuster class after interleukin inhibitors and JAKs?
A new frontier is emerging in the world of biologic therapies. After years of dominance by interleukin inhibitors…
argenx wins EU approval for subcutaneous VYVGART in CIDP, ending 30-year innovation drought in treatment
argenx gains EU approval for subcutaneous VYVGART in CIDP, reshaping autoimmune neurology care with a novel self-injection biologic.